Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2026-05-27 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 90% confidence The document is a Hong Kong Exchange Form FF305 “Next Day Disclosure Return” that reports changes in issued shares (new issue of H shares via placing) under listing rules. This is an announcement of a share issue/capital change. It does not present full financial statements or earnings, nor is it a general regulatory certification only. It directly concerns new share issuance details, fitting the Share Issue/Capital Change category.
2026-05-27 English
COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE
Share Issue/Capital Change Classification · 97% confidence The document is an announcement by a listed company reporting the completion of a placing of new H shares under its general mandate, including details of the number of shares placed, pricing, use of proceeds, and updated shareholding structure. It is clearly a share issuance/capital change notice rather than a full report or earnings update. This aligns with the Share Issue/Capital Change category.
2026-05-27 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 18 JUNE 2026 AT 10:30 A.M.
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a proxy form for the Annual General Meeting, used to solicit shareholder votes and specify voting instructions. This aligns with 'Proxy Solicitation & Information Statement' filings, which include materials sent to shareholders to provide information and request votes for meetings. Therefore, the correct classification is PSI.
2026-05-26 English
CIRCULAR OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a shareholder circular containing detailed information on items to be voted at the Annual General Meeting, including the notice of meeting, explanatory letters from the board, proposals (e.g., re-appointment of auditor, general mandates, amendments to articles), and proxy form instructions. It constitutes materials sent to shareholders to solicit votes and provide information ahead of the AGM, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL APPROVAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONE THERAPY FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER
Regulatory Filings Classification · 65% confidence The document is a voluntary announcement on the HKEx regarding clinical trial approval, containing no financial statements, not an earnings release or regulatory filing of a specific report. It is a general corporate announcement about a business development milestone. This falls under miscellaneous regulatory announcements, classified as Regulatory Filings (RNS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing), Inc. and Shanghai Allist Pharmaceuticals Co., Ltd. Announce a Collaboration Agreement to Jointly Evaluate the Combination of TT-00973-MS Tablets w
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by a Hong Kong listed company regarding a clinical trial collaboration agreement. It contains no financial results, governance changes, capital structuring, or formal report publications. It is not a full annual/interim report, earnings release, or specialized transaction filing. It is a general corporate announcement under listing rules, fitting the fallback category of Regulatory Filings (RNS).
2026-05-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.